209 related articles for article (PubMed ID: 34555842)
21. Mimicking the Acute Myeloid Leukemia Niche for Molecular Study and Drug Screening.
Houshmand M; Soleimani M; Atashi A; Saglio G; Abdollahi M; Nikougoftar Zarif M
Tissue Eng Part C Methods; 2017 Feb; 23(2):72-85. PubMed ID: 28007011
[TBL] [Abstract][Full Text] [Related]
22. Microenvironment signaling driving lymphomagenesis.
Verdière L; Mourcin F; Tarte K
Curr Opin Hematol; 2018 Jul; 25(4):335-345. PubMed ID: 29746265
[TBL] [Abstract][Full Text] [Related]
23. 3D modeling in cancer studies.
Atat OE; Farzaneh Z; Pourhamzeh M; Taki F; Abi-Habib R; Vosough M; El-Sibai M
Hum Cell; 2022 Jan; 35(1):23-36. PubMed ID: 34761350
[TBL] [Abstract][Full Text] [Related]
24. Impact of a Desmoplastic Tumor Microenvironment for Colon Cancer Drug Sensitivity: A Study with 3D Chimeric Tumor Spheroids.
Goudar VS; Koduri MP; Ta YN; Chen Y; Chu LA; Lu LS; Tseng FG
ACS Appl Mater Interfaces; 2021 Oct; 13(41):48478-48491. PubMed ID: 34633791
[TBL] [Abstract][Full Text] [Related]
25. COX-2-independent effects of celecoxib sensitize lymphoma B cells to TRAIL-mediated apoptosis.
Gallouet AS; Travert M; Bresson-Bepoldin L; Guilloton F; Pangault C; Caulet-Maugendre S; Lamy T; Tarte K; Guillaudeux T
Clin Cancer Res; 2014 May; 20(10):2663-73. PubMed ID: 24637636
[TBL] [Abstract][Full Text] [Related]
26. Pathology, pathogenesis and molecular genetics of follicular NHL.
Leich E; Ott G; Rosenwald A
Best Pract Res Clin Haematol; 2011 Jun; 24(2):95-109. PubMed ID: 21658611
[TBL] [Abstract][Full Text] [Related]
27. The yin and the yang of follicular lymphoma cell niches: role of microenvironment heterogeneity and plasticity.
Amé-Thomas P; Tarte K
Semin Cancer Biol; 2014 Feb; 24():23-32. PubMed ID: 23978491
[TBL] [Abstract][Full Text] [Related]
28. Immunopathology of non-Hodgkin lymphomas.
Huber H; Gattringer C; Knapp W; Stein H
Klin Wochenschr; 1984 Nov; 62(21):1001-10. PubMed ID: 6392723
[TBL] [Abstract][Full Text] [Related]
29. Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system?
Bladergroen BA; Meijer CJ; ten Berge RL; Hack CE; Muris JJ; Dukers DF; Chott A; Kazama Y; Oudejans JJ; van Berkum O; Kummer JA
Blood; 2002 Jan; 99(1):232-7. PubMed ID: 11756176
[TBL] [Abstract][Full Text] [Related]
30. A novel methionine aminopeptidase-2 inhibitor, PPI-2458, inhibits non-Hodgkin's lymphoma cell proliferation in vitro and in vivo.
Cooper AC; Karp RM; Clark EJ; Taghizadeh NR; Hoyt JG; Labenski MT; Murray MJ; Hannig G; Westlin WF; Thompson CD
Clin Cancer Res; 2006 Apr; 12(8):2583-90. PubMed ID: 16638869
[TBL] [Abstract][Full Text] [Related]
31. Simultaneous 2D and 3D cell culture array for multicellular geometry, drug discovery and tumor microenvironment reconstruction.
Li S; Yang K; Chen X; Zhu X; Zhou H; Li P; Chen Y; Jiang Y; Li T; Qin X; Yang H; Wu C; Ji B; You F; Liu Y
Biofabrication; 2021 Aug; 13(4):. PubMed ID: 34407511
[TBL] [Abstract][Full Text] [Related]
32. Formation of Lymphoma Hybrid Spheroids and Drug Testing in Real Time with the Use of Fluorescence Optical Tweezers.
Duś-Szachniewicz K; Gdesz-Birula K; Nowosielska E; Ziółkowski P; Drobczyński S
Cells; 2022 Jul; 11(13):. PubMed ID: 35805197
[TBL] [Abstract][Full Text] [Related]
33. Protein kinase CK2 is widely expressed in follicular, Burkitt and diffuse large B-cell lymphomas and propels malignant B-cell growth.
Pizzi M; Piazza F; Agostinelli C; Fuligni F; Benvenuti P; Mandato E; Casellato A; Rugge M; Semenzato G; Pileri SA
Oncotarget; 2015 Mar; 6(9):6544-52. PubMed ID: 25788269
[TBL] [Abstract][Full Text] [Related]
34. Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens.
Vidal-Crespo A; Matas-Céspedes A; Rodriguez V; Rossi C; Valero JG; Serrat N; Sanjuan-Pla A; Menéndez P; Roué G; López-Guillermo A; Giné E; Campo E; Colomer D; Bezombes C; van Bueren JL; Chiu C; Doshi P; Pérez-Galán P
Haematologica; 2020 Apr; 105(4):1032-1041. PubMed ID: 31296574
[TBL] [Abstract][Full Text] [Related]
35. B cell/stromal cell crosstalk in health, disease, and treatment: Follicular lymphoma as a paradigm.
Lamaison C; Tarte K
Immunol Rev; 2021 Jul; 302(1):273-285. PubMed ID: 34060097
[TBL] [Abstract][Full Text] [Related]
36. Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin α-4-β-1 (VLA-4) with natalizumab can overcome this resistance.
Mraz M; Zent CS; Church AK; Jelinek DF; Wu X; Pospisilova S; Ansell SM; Novak AJ; Kay NE; Witzig TE; Nowakowski GS
Br J Haematol; 2011 Oct; 155(1):53-64. PubMed ID: 21749361
[TBL] [Abstract][Full Text] [Related]
37. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
38. Integrating understanding of epidemiology and genomics in B-cell non-Hodgkin lymphoma as a pathway to novel management strategies.
Glass S; Phan A; Williams JN; Flowers CR; Koff JL
Discov Med; 2016 Mar; 21(115):181-8. PubMed ID: 27115168
[TBL] [Abstract][Full Text] [Related]
39. In silico analyses reveal common cellular pathways affected by loss of heterozygosity (LOH) events in the lymphomagenesis of Non-Hodgkin's lymphoma (NHL).
Aya-Bonilla C; Camilleri E; Haupt LM; Lea R; Gandhi MK; Griffiths LR
BMC Genomics; 2014 May; 15(1):390. PubMed ID: 24885312
[TBL] [Abstract][Full Text] [Related]
40. CD80 (B7.1) is expressed on both malignant B cells and nonmalignant stromal cells in non-Hodgkin lymphoma.
Dakappagari N; Ho SN; Gascoyne RD; Ranuio J; Weng AP; Tangri S
Cytometry B Clin Cytom; 2012 Mar; 82(2):112-9. PubMed ID: 22076940
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
